Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Glaucoma

Therapeutic area intelligence for Glaucoma with 20 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
20
Catalysts
0
Companies
7

Companies

AbbVie →
Alembic Pharmaceuticals →
FDC LTD →
Mankind Pharma →
Micro Labs →
THEA PHARMA →
Upsher Smith Labs →

Assets

Alcon →
Alembic →
Amneal →
Apotex →
FDA →
GLAND →
Glaucoma Underway →
MEMOPTIC →
Netarsudil →
XEN63 →

Recent signals(20)

RegulatoryAugust 6, 2026

FDA Approval Process for Brimonidine Tartrate by Micro Labs

The FDA has accepted the application ANDA218558 for Brimonidine Tartrate submitted by Micro Labs.

ClinicalAugust 2, 2026

Study Compares Goniotomy Devices for Glaucoma Treatment During Cataract Surgery

This study aims to evaluate the effectiveness of three goniotomy devices in controlling intraocular pressure and reducing glaucoma medication use post-surgery.

ClinicalAugust 1, 2026

Netarsudil Study Evaluates Trabecular Meshwork Changes in Glaucoma Patients

A study is underway to assess the effects of netarsudil on the trabecular meshwork in glaucoma patients using advanced imaging techniques.

ClinicalJuly 30, 2026

MEMOPTIC Trial Aims to Preserve Vision in Open-Angle Glaucoma Patients

The trial is investigating the efficacy of MEMOPTIC, a neuroprotective tablet, in preserving vision in patients with chronic open-angle glaucoma.

RegulatoryJuly 27, 2026

FDA Approves Brimonidine Tartrate Application ANDA220398 by Mankind Pharma

The FDA has approved the application ANDA220398 for Brimonidine Tartrate submitted by Mankind Pharma.

RegulatoryJuly 19, 2026

FDA Accepts Supplement for Brimonidine Tartrate by Apotex

The FDA has accepted a supplemental application for Brimonidine Tartrate submitted by Apotex.

StrategyJuly 19, 2026

Apotex Submits ANDA for Brimonidine Tartrate

Apotex has submitted an Abbreviated New Drug Application (ANDA) for Brimonidine Tartrate.

ClinicalJuly 19, 2026

PolyActiva's PA5346 Ocular Implant Trial for Glaucoma Underway

A clinical study is evaluating the efficacy, safety, and biodegradation of the PA5346 Ocular Implant in patients with open-angle glaucoma or ocular hypertension.

ClinicalJuly 15, 2026

Alcon initiates post-approval study for Hydrus Microstent malposition rates

Alcon Research is conducting a post-approval study to assess the malposition rate of the Hydrus Microstent within 24 months after implantation.

RegulatoryJuly 13, 2026

FDA Grants Approval for Brimonidine Tartrate ANDA218558 by Micro Labs

The FDA has granted approval for the ANDA218558 application for Brimonidine Tartrate submitted by Micro Labs.

RegulatoryJuly 9, 2026

Amneal's ANDA217288 for Brimonidine Tartrate and Timolol Maleate Receives AP Status

The FDA has granted Amneal's ANDA217288 application for Brimonidine Tartrate and Timolol Maleate an Abbreviated Approval (AP) status.

StrategyJuly 9, 2026

FDA Approves ANDA217934 for Brimonidine Tartrate and Timolol Maleate

The FDA has approved ANDA217934, a generic formulation containing Brimonidine Tartrate and Timolol Maleate.

RegulatoryJuly 4, 2026

FDA Grants Approval for Brimonidine Tartrate ANDA220398 by Mankind Pharma

The FDA has granted approval for the ANDA of Brimonidine Tartrate submitted by Mankind Pharma.

StrategyJuly 1, 2026

FDA Grants AP Status for Brimonidine Tartrate ANDA216772

The FDA has granted Abbreviated Approval (AP) status for ANDA216772, a generic formulation of Brimonidine Tartrate submitted by Upsher Smith Labs.

StrategyJune 27, 2026

FDA Grants Approval for Brimonidine Tartrate and Timolol Maleate ANDA219166

The FDA has granted approval for ANDA219166, a generic formulation containing Brimonidine Tartrate and Timolol Maleate.

RegulatoryJune 27, 2026

FDA Accepts Supplement Application for Brimonidine Tartrate by Regcon Holdings

The FDA has accepted a supplemental application (ANDA091691) for Brimonidine Tartrate from Regcon Holdings.

StrategyJune 21, 2026

FDA Grants AP Status for Dorzolamide Hydrochloride ANDA205294

The FDA has granted Abbreviated Approval (AP) status for ANDA205294, a generic formulation of Dorzolamide Hydrochloride.

RegulatoryJune 19, 2026

Alembic's ANDA215230 for Brimonidine Tartrate and Timolol Maleate Receives AP Status

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status of AP for Alembic's formulation of Brimonidine Tartrate and Timolol Maleate.

ClinicalJune 19, 2026

AbbVie Evaluates XEN63 Gel Stent for Glaucoma via Two Surgical Approaches

A clinical trial is underway to assess the safety and effectiveness of the XEN63 gel stent in glaucoma patients using two different surgical approaches.

RegulatoryJune 6, 2026

FDA Accepts Application for COSOPT PF Supplement by THEA PHARMA

The FDA has accepted the supplemental application NDA202667 for COSOPT PF, a glaucoma treatment.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.